Enanta Pharmaceuticals, Inc.
ENTA
$13.85
$0.010.07%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -11.94M | -18.70M | -18.26M | -22.64M | -22.29M |
| Total Depreciation and Amortization | 1.23M | 1.28M | 1.21M | 1.20M | 889.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.89M | 5.54M | 2.25M | 5.84M | 4.49M |
| Change in Net Operating Assets | -2.88M | 5.38M | 32.30M | 2.11M | 113.00K |
| Cash from Operations | -11.70M | -6.49M | 17.51M | -13.49M | -16.80M |
| Capital Expenditure | -143.00K | -1.46M | -155.00K | -2.54M | -8.75M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -47.16M | 3.75M | -26.33M | -1.83M | 77.65M |
| Cash from Investing | -47.30M | 2.30M | -26.48M | -4.37M | 68.90M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 74.89M | 51.00K | 0.00 | 0.00 | 94.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -10.76M | -8.37M | -6.42M | -6.89M | -5.08M |
| Cash from Financing | 64.14M | -8.32M | -6.42M | -6.89M | -4.99M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 5.14M | -12.51M | -15.40M | -24.74M | 47.12M |